Last reviewed · How we verify
cordyceps sinesis capsule
Cordyceps sinensis capsule, marketed by Bin Cao, is a currently available product with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent protection provides a competitive advantage until expiry. The lack of detailed revenue and clinical trial data poses a significant risk in assessing its market performance and potential threats from competitors.
At a glance
| Generic name | cordyceps sinesis capsule |
|---|---|
| Sponsor | Bin Cao |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cordyceps sinesis capsule CI brief — competitive landscape report
- cordyceps sinesis capsule updates RSS · CI watch RSS
- Bin Cao portfolio CI